Latest From Incyte Corp.
Janssen’s two investigational Ebola vaccines are among four new products recently granted fast-track review by the European Medicines Agency. GlaxoSmithKline and Viiv Healthcare are not disclosing the outcomes of accelerated assessment requests they have made.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent deals, AstraZeneca sells Seroquel, Losec rights to Germany’s Cheplapharm.
The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Incyte Pharmaceuticals Inc.
- Incyte Genomics Inc.
- North America
- Parent & Subsidiaries
- Incyte Corp.
- Senior Management
Hervé A Hoppenot, MD, Pres. & CEO
Christiana Stamoulis, EVP, CFO
Dashyant Dhanak , PhD, EVP, CSO
Vijay Iyengar, MD, EVP, Global Strategy & Corp. Dev.
Steven H Stein, MD, EVP, CMO
- Contact Info
Phone: (302) 498-6700
1801 Augustine Cut-Off
Wilmington, DE 19803
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.